Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Brian Bolwell, MD, is the Chairman of Taussig Cancer Institute at Cleveland Clinic in addition to being Chairman of the Department of Hematologic Oncology and Blood Disorders. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and has authored more than 300 articles and abstracts concerning hematologic malignancies and bone marrow transplantation. He also has edited a book entitled “Current Controversies in Bone Marrow Transplantation.” (Humana Press, 2000), and he is co-editor of a recently published textbook entitled “Clinical Malignant Hematology” (McGraw-Hill, 2007).
He attended Harvard University and he received his medical degree from Case Western Reserve University. He completed his medical internship and residency at University Hospitals of Cleveland and completed his hematology/oncology fellowship at the Hospital of the University of Pennsylvania.
Dr. Bolwell is a reviewer for many journals including the Journal of Clinical Oncology, Blood, Annals of Internal Medicine and Bone Marrow Transplantation. He has served, on multiple occasions, as a Bone Marrow Transplant (BMT) abstract reviewer and abstract session coordinating reviewer at the American Society of Hematology Annual meetings.
He has held the position of Chairman of the Board of Trustees of the Ohio Hematopoietic Stem Cell Transplant Consortium for more than 10 years. In 2004, he was elected to the Executive Committee of the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry. He is a member of the Board of Governors of Cleveland Clinic.
Bone marrow transplantation (BMT), hematologic malignancies, Hodgkins Disease/lymphoma, non-Hodgkins lymphoma, lymphoma, cancer
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/1/2013, Dr. Bolwell has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.